Probi AB has invested approximately NZD 9 million in newly issued shares in Blis Technologies Ltd. In connection with the investment, Blis Technologies and Probi AB have signed a licensing and distribution agreement which means that Probi will manufacture Blis bacterial strains and offer these to Probi's customers around the world. The companies will furthermore collaborate in research and development.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.017 NZD | -10.53% | +6.25% | -10.53% |
Apr. 15 | New Zealand Shares Close Flat on Monday; Blis Technologies Upgrades Fiscal 2024 Guidance | MT |
Apr. 15 | Blis Technologies Upgrades Fiscal 2024 Guidance | MT |
1st Jan change | Capi. | |
---|---|---|
-10.53% | 12.84M | |
+20.40% | 44.1B | |
+17.11% | 21.97B | |
+8.10% | 13.27B | |
+6.32% | 13.22B | |
+35.95% | 11.36B | |
-8.53% | 7.07B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+10.09% | 5.23B |
- Stock Market
- Equities
- BLT Stock
- News BLIS Technologies Limited
- Blis Technologies and Probi AB Signs a Licensing and Distribution Agreement